Q3 Earnings Forecast for Neurogene Issued By Leerink Partnrs

Neurogene Inc. (NASDAQ:NGNE) – Leerink Partnrs reduced their Q3 2025 EPS estimates for shares of Neurogene in a note issued to investors on Monday, August 11th. Leerink Partnrs analyst M. Foroohar now expects that the company will earn ($1.18) per share for the quarter, down from their prior estimate of ($1.14). The consensus estimate for Neurogene’s current full-year earnings is ($4.27) per share. Leerink Partnrs also issued estimates for Neurogene’s Q4 2025 earnings at ($1.30) EPS, FY2025 earnings at ($4.61) EPS and FY2026 earnings at ($5.97) EPS.

Neurogene (NASDAQ:NGNE) last announced its quarterly earnings results on Monday, August 11th. The company reported ($1.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.15) by $0.10.

NGNE has been the topic of a number of other research reports. HC Wainwright dropped their price target on Neurogene from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. Baird R W downgraded shares of Neurogene from a “strong-buy” rating to a “hold” rating in a report on Friday, May 16th. BMO Capital Markets restated an “outperform” rating and set a $26.00 target price (up previously from $22.00) on shares of Neurogene in a research note on Thursday, June 12th. Craig Hallum assumed coverage on shares of Neurogene in a report on Tuesday, June 17th. They set a “buy” rating and a $50.00 target price for the company. Finally, Robert W. Baird lowered shares of Neurogene from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $38.00 to $24.00 in a research note on Friday, May 16th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $46.17.

Neurogene Trading Up 1.5%

Shares of NASDAQ NGNE opened at $20.51 on Thursday. The company has a market capitalization of $292.68 million, a P/E ratio of -4.76 and a beta of 1.69. Neurogene has a 12 month low of $6.88 and a 12 month high of $74.49. The stock has a 50 day moving average of $20.34 and a 200-day moving average of $17.28.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of America Corp DE raised its position in shares of Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after buying an additional 42,880 shares in the last quarter. Schroder Investment Management Group acquired a new position in Neurogene in the 2nd quarter valued at $451,000. PNC Financial Services Group Inc. lifted its position in shares of Neurogene by 43.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock valued at $61,000 after acquiring an additional 1,232 shares during the period. Jennison Associates LLC grew its holdings in shares of Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after purchasing an additional 59,479 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Neurogene by 17.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the period. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.